Cardiovascular adverse event according to general anesthesia techniques in end-stage renal disease patients

The influence of propofol-based total intravenous anesthesia on postoperative outcomes in end-stage renal disease patients: A prospective randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0007790

Enrollment

600

Registered

2022-10-07

Start date

2022-10-31

Completion date

Unknown

Last updated

2022-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : In the TIVA group, 40 mg of 2% lidocaine was administered, 2% propofol and remifentanil were administered for anesthesia induction and maintenance, and a target-controlled infusion system (TCI)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: End-stage renal disease patients undergoing surgery under general anesthesia

Exclusion criteria

Exclusion criteria: Heart surgery, transplant surgery, cancer surgery, emergency surgery Patients who underwent general anesthesia within 1 month prior to study enrollment and patients who underwent cardiovascular angiography within 1 month

Design outcomes

Primary

Measure	Time frame
Major adverse cardiovascular event	—

Secondary

Measure	Time frame
hypotension during surgery	—

Countries

Korea, Republic of

Contacts

Public ContactSanghoon Song

Soon Chun Hyang University Hospital Seoul

112226@schmc.ac.kr+82-2-709-9302

Outcome results